JP2010090130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010090130A5 JP2010090130A5 JP2009263603A JP2009263603A JP2010090130A5 JP 2010090130 A5 JP2010090130 A5 JP 2010090130A5 JP 2009263603 A JP2009263603 A JP 2009263603A JP 2009263603 A JP2009263603 A JP 2009263603A JP 2010090130 A5 JP2010090130 A5 JP 2010090130A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- arg
- phe
- seq
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 80
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 claims 59
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 claims 59
- 239000000018 receptor agonist Substances 0.000 claims 57
- 229940044601 receptor agonist Drugs 0.000 claims 57
- 239000008194 pharmaceutical composition Substances 0.000 claims 42
- 150000003839 salts Chemical class 0.000 claims 41
- 230000005714 functional activity Effects 0.000 claims 36
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 claims 32
- 102000057094 human MC4R Human genes 0.000 claims 32
- 230000001939 inductive effect Effects 0.000 claims 30
- 206010006895 Cachexia Diseases 0.000 claims 28
- 102000004378 Melanocortin Receptors Human genes 0.000 claims 28
- 108090000950 Melanocortin Receptors Proteins 0.000 claims 28
- 201000010099 disease Diseases 0.000 claims 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 28
- 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 claims 24
- 102000056592 human MC3R Human genes 0.000 claims 24
- 230000028327 secretion Effects 0.000 claims 24
- 125000002252 acyl group Chemical group 0.000 claims 22
- 230000001270 agonistic effect Effects 0.000 claims 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 20
- 230000003042 antagnostic effect Effects 0.000 claims 19
- 208000007848 Alcoholism Diseases 0.000 claims 16
- 102000030612 Melanocortin 5 receptor Human genes 0.000 claims 16
- 108010088565 Melanocortin 5 receptor Proteins 0.000 claims 16
- 102000005962 receptors Human genes 0.000 claims 16
- 108020003175 receptors Proteins 0.000 claims 16
- -1 D-1-Nal Chemical compound 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 13
- 229960002870 gabapentin Drugs 0.000 claims 13
- 230000037406 food intake Effects 0.000 claims 12
- 235000012631 food intake Nutrition 0.000 claims 12
- 208000030159 metabolic disease Diseases 0.000 claims 12
- 208000016261 weight loss Diseases 0.000 claims 12
- 230000004580 weight loss Effects 0.000 claims 12
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 11
- 239000000556 agonist Substances 0.000 claims 11
- 230000002401 inhibitory effect Effects 0.000 claims 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims 10
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 10
- 208000030814 Eating disease Diseases 0.000 claims 10
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 10
- 208000008589 Obesity Diseases 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 208000016097 disease of metabolism Diseases 0.000 claims 10
- 235000014632 disordered eating Nutrition 0.000 claims 10
- 235000020824 obesity Nutrition 0.000 claims 10
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims 9
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 8
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 8
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 8
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 claims 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 8
- 108010008364 Melanocortins Proteins 0.000 claims 8
- 206010040070 Septic Shock Diseases 0.000 claims 8
- 206010001584 alcohol abuse Diseases 0.000 claims 8
- 208000025746 alcohol use disease Diseases 0.000 claims 8
- 230000006399 behavior Effects 0.000 claims 8
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 8
- 208000016253 exhaustion Diseases 0.000 claims 8
- 125000004404 heteroalkyl group Chemical group 0.000 claims 8
- 102000054812 human MC1R Human genes 0.000 claims 8
- 239000002865 melanocortin Substances 0.000 claims 8
- 230000036303 septic shock Effects 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 7
- 230000037396 body weight Effects 0.000 claims 7
- 230000012010 growth Effects 0.000 claims 7
- 208000030507 AIDS Diseases 0.000 claims 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 6
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 6
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 208000032841 Bulimia Diseases 0.000 claims 6
- 206010006550 Bulimia nervosa Diseases 0.000 claims 6
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 6
- 201000009273 Endometriosis Diseases 0.000 claims 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 201000005569 Gout Diseases 0.000 claims 6
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 6
- 208000012641 Pigmentation disease Diseases 0.000 claims 6
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 6
- 102000003946 Prolactin Human genes 0.000 claims 6
- 108010057464 Prolactin Proteins 0.000 claims 6
- 201000004681 Psoriasis Diseases 0.000 claims 6
- 206010063837 Reperfusion injury Diseases 0.000 claims 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 6
- 206010040047 Sepsis Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 6
- 206010052779 Transplant rejections Diseases 0.000 claims 6
- 206010046788 Uterine haemorrhage Diseases 0.000 claims 6
- 208000021017 Weight Gain Diseases 0.000 claims 6
- 206010052428 Wound Diseases 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 6
- 206010000496 acne Diseases 0.000 claims 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 6
- 229960002478 aldosterone Drugs 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 6
- 230000007815 allergy Effects 0.000 claims 6
- 208000022531 anorexia Diseases 0.000 claims 6
- 230000036506 anxiety Effects 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 6
- 230000036772 blood pressure Effects 0.000 claims 6
- 230000036760 body temperature Effects 0.000 claims 6
- 230000008468 bone growth Effects 0.000 claims 6
- 208000025698 brain inflammatory disease Diseases 0.000 claims 6
- 230000003727 cerebral blood flow Effects 0.000 claims 6
- 238000002512 chemotherapy Methods 0.000 claims 6
- 206010061428 decreased appetite Diseases 0.000 claims 6
- 238000000502 dialysis Methods 0.000 claims 6
- 206010014599 encephalitis Diseases 0.000 claims 6
- 230000029142 excretion Effects 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 230000006058 immune tolerance Effects 0.000 claims 6
- 201000001881 impotence Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 208000028867 ischemia Diseases 0.000 claims 6
- 208000011379 keloid formation Diseases 0.000 claims 6
- 230000013016 learning Effects 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 230000007074 memory dysfunction Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000008450 motivation Effects 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 210000005036 nerve Anatomy 0.000 claims 6
- 208000004296 neuralgia Diseases 0.000 claims 6
- 208000021722 neuropathic pain Diseases 0.000 claims 6
- 230000004112 neuroprotection Effects 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 230000011164 ossification Effects 0.000 claims 6
- 230000037324 pain perception Effects 0.000 claims 6
- 239000003016 pheromone Substances 0.000 claims 6
- 230000028742 placenta development Effects 0.000 claims 6
- 229940097325 prolactin Drugs 0.000 claims 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 210000002374 sebum Anatomy 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 230000036332 sexual response Effects 0.000 claims 6
- 230000035939 shock Effects 0.000 claims 6
- 201000000849 skin cancer Diseases 0.000 claims 6
- 229910052708 sodium Inorganic materials 0.000 claims 6
- 239000011734 sodium Substances 0.000 claims 6
- 208000020431 spinal cord injury Diseases 0.000 claims 6
- 238000003786 synthesis reaction Methods 0.000 claims 6
- 229940034208 thyroxine Drugs 0.000 claims 6
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 6
- 230000001052 transient effect Effects 0.000 claims 6
- 230000006442 vascular tone Effects 0.000 claims 6
- 230000004584 weight gain Effects 0.000 claims 6
- 235000019786 weight gain Nutrition 0.000 claims 6
- 230000004097 bone metabolism Effects 0.000 claims 5
- 230000021595 spermatogenesis Effects 0.000 claims 5
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000030090 Acute Disease Diseases 0.000 claims 4
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000037976 chronic inflammation Diseases 0.000 claims 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 230000002611 ovarian Effects 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- 230000002829 reductive effect Effects 0.000 claims 4
- 210000004994 reproductive system Anatomy 0.000 claims 4
- 230000001568 sexual effect Effects 0.000 claims 4
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 208000001953 Hypotension Diseases 0.000 claims 3
- 206010007625 cardiogenic shock Diseases 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 208000021822 hypotensive Diseases 0.000 claims 3
- 230000001077 hypotensive effect Effects 0.000 claims 3
- 230000009593 intrauterine fetal growth Effects 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims 2
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 206010021137 Hypovolaemia Diseases 0.000 claims 2
- 150000008575 L-amino acids Chemical class 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 230000009602 intrauterine growth Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 230000032696 parturition Effects 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims 1
- 210000003754 fetus Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69777905P | 2005-07-08 | 2005-07-08 | |
| US60/697,779 | 2005-07-08 | ||
| US74885005P | 2005-12-09 | 2005-12-09 | |
| US60/748,850 | 2005-12-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008520417A Division JP4734411B2 (ja) | 2005-07-08 | 2006-07-10 | メラノコルチン受容体リガンド |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013165312A Division JP2013253090A (ja) | 2005-07-08 | 2013-08-08 | メラノコルチン受容体リガンド |
| JP2015140154A Division JP5965520B2 (ja) | 2005-07-08 | 2015-07-14 | メラノコルチン受容体リガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010090130A JP2010090130A (ja) | 2010-04-22 |
| JP2010090130A5 true JP2010090130A5 (OSRAM) | 2011-06-23 |
| JP5889513B2 JP5889513B2 (ja) | 2016-03-22 |
Family
ID=37637790
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008520417A Active JP4734411B2 (ja) | 2005-07-08 | 2006-07-10 | メラノコルチン受容体リガンド |
| JP2009263603A Active JP5889513B2 (ja) | 2005-07-08 | 2009-11-19 | メラノコルチン受容体リガンド |
| JP2013165312A Pending JP2013253090A (ja) | 2005-07-08 | 2013-08-08 | メラノコルチン受容体リガンド |
| JP2015140154A Active JP5965520B2 (ja) | 2005-07-08 | 2015-07-14 | メラノコルチン受容体リガンド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008520417A Active JP4734411B2 (ja) | 2005-07-08 | 2006-07-10 | メラノコルチン受容体リガンド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013165312A Pending JP2013253090A (ja) | 2005-07-08 | 2013-08-08 | メラノコルチン受容体リガンド |
| JP2015140154A Active JP5965520B2 (ja) | 2005-07-08 | 2015-07-14 | メラノコルチン受容体リガンド |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US8039435B2 (OSRAM) |
| EP (6) | EP3354273B1 (OSRAM) |
| JP (4) | JP4734411B2 (OSRAM) |
| KR (2) | KR101232201B1 (OSRAM) |
| CN (5) | CN119119190A (OSRAM) |
| AU (2) | AU2006269261B2 (OSRAM) |
| CA (4) | CA2793119C (OSRAM) |
| DK (4) | DK3354273T3 (OSRAM) |
| ES (4) | ES2663916T3 (OSRAM) |
| FR (1) | FR21C1060I2 (OSRAM) |
| HU (4) | HUE031731T2 (OSRAM) |
| IL (3) | IL188545A (OSRAM) |
| NL (1) | NL301150I2 (OSRAM) |
| NZ (2) | NZ565217A (OSRAM) |
| PL (4) | PL2286825T3 (OSRAM) |
| PT (4) | PT3354273T (OSRAM) |
| RU (2) | RU2439079C2 (OSRAM) |
| SG (1) | SG163585A1 (OSRAM) |
| SI (1) | SI3354273T1 (OSRAM) |
| WO (1) | WO2007008704A2 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4734411B2 (ja) * | 2005-07-08 | 2011-07-27 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンド |
| DE102007020152A1 (de) * | 2007-04-26 | 2008-10-30 | Charité - Universitätsmedizin Berlin | Mittel zur antiinfektiven Behandlung eines Patienten |
| US8563000B2 (en) | 2007-05-25 | 2013-10-22 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| TW200848424A (en) * | 2007-06-15 | 2008-12-16 | Sod Conseils Rech Applic | Cyclic peptide melanocortin receptor ligands |
| CN101980717A (zh) * | 2007-11-05 | 2011-02-23 | 益普生制药股份有限公司 | 黑皮质素治疗胰岛素敏感的应用 |
| EP2816055B1 (en) | 2008-05-27 | 2018-12-19 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormons |
| CA2727317C (en) | 2008-06-09 | 2015-02-17 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| CA2761607C (en) | 2009-06-08 | 2018-09-04 | Yi-Qun Shi | Melanocortin receptor-specific peptides |
| IN2012DN01493A (OSRAM) * | 2009-08-05 | 2015-06-05 | Ipsen Pharma Sas | |
| HUE031856T2 (en) * | 2009-08-31 | 2017-08-28 | Tensive Controls Inc | Stabilized melanocortin ligands |
| CN102686601A (zh) * | 2009-11-16 | 2012-09-19 | 益普生制药股份有限公司 | 合成Ac-Arg-环(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2的方法 |
| EP2501225B1 (en) | 2009-11-16 | 2017-11-01 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
| CA2781402C (en) | 2009-11-23 | 2017-03-21 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| EA201290295A1 (ru) | 2009-11-23 | 2013-01-30 | Палатин Текнолоджиз, Инк. | Специфичные к рецептору меланокортина-1 линейные пептиды |
| JP6072020B2 (ja) * | 2011-06-14 | 2017-02-01 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | メラノコルチンリセプターリガンドを有効成分として含有する持続放出性組成物 |
| LT3539551T (lt) | 2011-12-29 | 2022-01-10 | Rhythm Pharmaceuticals, Inc. | Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose |
| EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
| EP2722340B1 (en) | 2012-10-19 | 2015-03-04 | TXP Pharma GmbH | Alpha- and gamma-MSH analogues |
| EP2968475A2 (en) | 2013-03-14 | 2016-01-20 | Questcor Pharmaceuticals, Inc. | Acth for treatment of acute respiratory distress syndrome |
| EP2970389B1 (en) * | 2013-03-15 | 2020-08-19 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical compositions |
| US10196425B2 (en) | 2013-03-15 | 2019-02-05 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| BR112016024494B1 (pt) | 2014-04-22 | 2024-02-06 | Txp Pharma Gmbh | Análogo de peptídeo e seu uso |
| PT3356386T (pt) * | 2015-09-30 | 2024-05-17 | Rhythm Pharmaceuticals Inc | Método de tratamento de distúrbios associados à via do receptor da melanocortina-4 |
| US11542302B2 (en) | 2015-10-15 | 2023-01-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulators of melanocortin receptors for the treatment of depression and anxiety |
| US10653743B2 (en) * | 2015-10-15 | 2020-05-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N |
| US20190255142A1 (en) * | 2016-10-17 | 2019-08-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Novel modulators of melanocortin receptors for the treatment of depression and anxiety |
| MA49883A (fr) * | 2017-03-15 | 2021-04-21 | Novo Nordisk As | Composés bicycliques aptes à se lier au récepteur de mélanocortine 4 |
| EP3773897A1 (en) | 2018-04-06 | 2021-02-17 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
| US20210221867A1 (en) * | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
| CA3100868A1 (en) * | 2018-05-23 | 2019-11-28 | Provincial Health Services Authority | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy |
| US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
| AR123603A1 (es) * | 2020-09-24 | 2022-12-21 | Rhythm Pharmaceuticals Inc | Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina |
| WO2022251650A1 (en) * | 2021-05-27 | 2022-12-01 | The Regents Of The University Of Michigan | Mc3r agonist peptides |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2025123059A1 (en) * | 2023-12-07 | 2025-06-12 | Endevica Bio, Inc. | Non-naturally occurring melanocortin analogs and uses thereof for treating substance use disorders |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US613874A (en) | 1898-11-08 | George e | ||
| US1613874A (en) | 1922-03-29 | 1927-01-11 | Miner Inc W H | Friction draft gear |
| US5652214A (en) | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| SE9700620D0 (sv) | 1997-02-21 | 1997-02-21 | Wapharm Ab | Cykliska peptider med selektivitet för MSH-receptor subtyper |
| US6350430B1 (en) | 1997-10-27 | 2002-02-26 | Lion Bioscience Science Ag | Melanocortin receptor ligands and methods of using same |
| US6127381A (en) * | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| EP1100970A2 (en) * | 1998-07-27 | 2001-05-23 | Iowa State University Research Foundation, Inc. | Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals |
| AU775289B2 (en) | 1998-08-21 | 2004-07-29 | Children's Medical Center Corporation | Use of melanin for inhibition of angiogenesis and macular degeneration |
| US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
| US6716810B1 (en) | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
| KR100519201B1 (ko) * | 1999-03-29 | 2005-10-06 | 더 프록터 앤드 갬블 캄파니 | 멜라노코르틴 수용체 리간드 |
| WO2003006620A2 (en) * | 2001-07-11 | 2003-01-23 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptides |
| US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| AU1758401A (en) | 1999-11-12 | 2001-06-06 | Merck & Co., Inc. | Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| AP2001002196A0 (en) * | 2000-06-28 | 2002-12-21 | Pfizer Prod Inc | Melanocortin receptor ligands. |
| US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
| JP2004510960A (ja) | 2000-09-13 | 2004-04-08 | エレノア ルーズベルト インスティテュート | 肥満および糖尿病におけるインスリン抵抗性を治療する方法 |
| US20030113263A1 (en) | 2001-02-13 | 2003-06-19 | Oregon Health And Sciences University, A Non-Profit Organization | Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia |
| HUP0401544A2 (hu) | 2001-03-02 | 2004-12-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
| US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| US7034004B2 (en) | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
| US20040128136A1 (en) * | 2002-09-20 | 2004-07-01 | Irani Pourang Polad | Internet voice browser |
| AU2004251616A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
| WO2005000338A1 (en) | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| US20070293423A1 (en) | 2003-08-20 | 2007-12-20 | Eli Lilly And Company | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide |
| EP1658273B1 (en) | 2003-08-20 | 2007-01-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| WO2005040109A1 (en) * | 2003-10-22 | 2005-05-06 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| DE10355559A1 (de) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
| US20070155660A1 (en) | 2003-12-10 | 2007-07-05 | Marsh Donald J | Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists |
| CA2557739A1 (en) * | 2004-03-29 | 2005-11-03 | Eli Lilly And Company | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion |
| US8569234B2 (en) | 2004-10-08 | 2013-10-29 | Clinuvel Pharmaceuticals Limited | Compositions and methods for including melanogenesis in a subject |
| WO2006073772A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| WO2006073771A2 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| JP4734411B2 (ja) * | 2005-07-08 | 2011-07-27 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンド |
| US8466104B2 (en) | 2005-08-26 | 2013-06-18 | Abbvie Inc. | Therapeutically active alpha MSH analogues |
-
2006
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/ja active Active
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/es active Active
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 PL PL10182566T patent/PL2286825T3/pl unknown
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/es active Active
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/da active
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/ko active Active
- 2006-07-10 CN CN202411273113.9A patent/CN119119190A/zh active Pending
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en active Active
- 2006-07-10 SI SI200632406T patent/SI3354273T1/sl unknown
- 2006-07-10 CN CN200910174061A patent/CN101676298A/zh active Pending
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 PT PT172028367T patent/PT3354273T/pt unknown
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/zh active Active
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en active Active
- 2006-07-10 CA CA2793119A patent/CA2793119C/en active Active
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en active Active
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/ko active Active
- 2006-07-10 PT PT121887848T patent/PT2548568T/pt unknown
- 2006-07-10 PL PL12188784T patent/PL2548568T3/pl unknown
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/ru active
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 CN CN201610168908.2A patent/CN105837661B/zh active Active
- 2006-07-10 PL PL10170694T patent/PL2236151T3/pl unknown
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/da active
- 2006-07-10 PL PL17202836T patent/PL3354273T3/pl unknown
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/hu unknown
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 PT PT10170694T patent/PT2236151E/pt unknown
- 2006-07-10 PT PT101825669T patent/PT2286825T/pt unknown
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en not_active Ceased
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en active Active
- 2006-07-10 ES ES17202836T patent/ES2877349T3/es active Active
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/hu unknown
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/ru active
- 2006-07-10 ES ES10170694T patent/ES2386862T3/es active Active
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en active Active
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/zh active Active
- 2006-07-10 CA CA2614615A patent/CA2614615C/en active Active
-
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
-
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en active Active
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/ja active Active
-
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
-
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/ja active Pending
-
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/ja active Active
-
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en active Active
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
-
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
-
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/nl unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/fr active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/hu unknown
-
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010090130A5 (OSRAM) | ||
| RU2401841C2 (ru) | Лиганды рецепторов меланокортинов | |
| RU2009131092A (ru) | Лиганды рецепторов меланокортинов | |
| JP2009500427A5 (OSRAM) | ||
| CA2689016A1 (en) | Melanocortin receptor ligands modified with hydantoin | |
| KR101226165B1 (ko) | 피부 외용제 조성물 | |
| US6262021B1 (en) | Use of substances having oxytocin activity for preparation of medicaments for wound healing | |
| TWI619505B (zh) | 脫毛症治療劑 | |
| TWI374030B (en) | Use of melanocortins to treat insulin sensitivity | |
| Blank et al. | Actions of CRF and its analogs | |
| JP2021102650A5 (OSRAM) | ||
| TW201601743A (zh) | 外周ｋａｐｐａ鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途 | |
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| CN108135965B (zh) | 用于伤口愈合的含p物质的药物组合物 | |
| Lippert et al. | Effects of oxytocin outside pregnancy | |
| Stern | Nursing posture is elicited rapidly in maternally naive, haloperidol-treated female and male rats in response to ventral trunk stimulation from active pups | |
| RU2012106302A (ru) | Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59 | |
| JP6800372B2 (ja) | 持続型パルミチン酸結合ＧｎＲＨ誘導体及びこれを含む薬剤学的組成物 | |
| CN110935007B (zh) | 利那洛肽复方组合物、制剂及其用途和制备方法 | |
| AU2016302644A1 (en) | CNP cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide | |
| CN102631663B (zh) | 一种治疗男性不育、阳痿早泄的制剂及其应用 | |
| Kawakami | Electro-myographic study of the human abdominal muscles affected by sexual hormones | |
| WO2017088177A1 (zh) | 贻贝粘蛋白产品及其预防和抑制神经炎症的应用 | |
| TW202116347A (zh) | 肽及其作為製備治療發炎性疾病及疼痛的藥物的用途 | |
| Laurent et al. | TGF-beta antibodies: a novel treatment for pulmonary fibrosis? |